25 results on '"Todorovski, Izabela"'
Search Results
2. Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
3. Supplementary Table from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
4. Data from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
5. Supplementary Figure from Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
6. Data from CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory
7. TableS1.xlsx from CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory
8. Supplementary Figures from CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory
9. RNA decay defines the response to transcriptional perturbation in leukaemia
10. Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML
11. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer
12. CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory
13. Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition
14. SUGAR-seq enables simultaneous detection of glycans, epitopes, and the transcriptome in single cells
15. Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD–Driven Acute Myeloid Leukemia
16. IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors
17. Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation
18. Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit
19. 3002 – REPROGRAMMING OF SERINE METABOLISM IS A METABOLIC VULNERABILITY IN FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTANT ACUTE MYELOID LEUKAEMIA
20. A PP2A-Integrator complex fine-tunes transcription by opposing CDK9
21. Reprogramming of serine metabolism is an actionable vulnerability in FLT3-ITD driven acute myeloid leukaemia
22. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity
23. Abstract 4295: AZ’5576, a selective CDK9 inhibitor, demonstratesin vitroandin vivoactivity in diverse preclinical models of non-Hodgkin lymphoma
24. Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene
25. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.